AGILENT TECHNOLOGIES, INC. (A) Stock
A has an Alpha Score of 50 out of 100 (weak), computed on Nov 6, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 20 trades in A since 2014: 8 purchases and 12 sales, most recently Julie Johnson (purchase, Sep 23, 2025). 4 of the hedge funds AlphaScala tracks reported A in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $197.41M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 5, 2026. Its trailing P/E ratio is 34.7 and its net margin 19.5% (key statistics as of Nov 4, 2026).
What is A's Alpha Score?
How it works →Alpha Score of 50 reflects moderate overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded AGILENT TECHNOLOGIES, INC. (A)?
Most recent: Julie Johnson (purchase, Sep 23, 2025); records start Oct 2, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Julie Johnson D-TX · House | 2025-09-23 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-09-23 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-16 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Jefferson Shreve R-IN · House | 2025-04-17 | purchase | $15k – $50k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded A, with filing lags →Which hedge funds own A?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.49M | $197.41M | -12% |
| Citadel Ken Griffin | 1.10M | $146.31M | -39% |
| Millennium Management Israel Englander | 92K | $12.21M | -87% |
| Bridgewater Associates Ray Dalio | 23K | $3.04M | -69% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are AGILENT TECHNOLOGIES, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Dolsten Mikael | Director | SELL | 634 | $96K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are A's key statistics?
Key statistics as of Nov 4, 2026
How does A's valuation compare with the Healthcare sector?
| Metric | A | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 34.7 | 28.7 | 108 |
| Net margin | 19.53% | 4.11% | 160 |
| Return on equity | 20.47% | 5.18% | 180 |
| Dividend yield (payers) | 0.75% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
A price chart
Powered by TradingViewWhat does AGILENT TECHNOLOGIES, INC. do?
Agilent Technologies Inc. provides application-focused solutions for life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three key segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment delivers instruments, software, and services to identify, quantify, and analyze physical and biological properties of substances, supporting clinical and life sciences research at molecular and cellular levels. The Diagnostics and Genomics segment supplies reagents, instruments, software, consumables, and active pharmaceutical ingredients for oligo-based therapeutics, advancing genomics, pathology, and companion diagnostics. Agilent CrossLab offers startup support, operational training, compliance services, software-as-a-service, asset management, and consultative services to optimize laboratory performance. Notable products include liquid chromatography systems, mass spectrometry, and innovations like the Altura line of HPLC columns for biotherapeutic testing, xCELLigence RTCA eSight with 21 CFR Part 11 compliance software, and Insight Series for airport security screening. Founded in 1999 and headquartered in Santa Clara, California, Agilent Technologies Inc. plays a vital role in enabling scientific breakthroughs across pharmaceuticals, biotechnology, and environmental testing.